NielsenIQ Expands NIQ Product Insights, Enabling Retailers and Brands to Better Navigate Global Challenges from Tariffs

8.5.2025 11:00:00 EEST | Business Wire | Press release

NielsenIQ (NIQ), the leader in consumer intelligence, today announced the global expansion of NIQ Product Insights (NPI), its market-leading solutions offering that provides CPG and retail enterprises with an extensive catalogue detailing the specific product attributes—such as dietary, sustainability, and clean label characteristics—consumers search for when they shop. Already adopted by leading retailers and CPG manufacturers in the U.S., NPI will expand to 25 additional markets within Western Europe, Eastern Europe, the Middle East, and Latin America throughout 2025 and 2026.

NPI empowers brands and retailers to stay ahead of global macroeconomic challenges—whether that is changing regulatory standards or tariff impacts—shifting consumer preferences, and category trends with the most granular product-level data in the industry. The solution, which combines NIQ's comprehensive market measurement with generative AI technology , delivers 27,000+ structured product attributes per SKU and resolves 99% of consumer queries, ranging from whether a product is GLP-1 friendly, gluten-free, or made in one's home country, in addition to the many other attributes that matter most to today’s consumers.

“In a complex consumer environment defined by increasing competition and more discerning consumers, retailers have the added pressure of tariffs and inflation impacting their product choices and go-to-market decisions. Our NIQ Product Insights provides analytics and insights to help companies understand changes in global regulation, including origin labeling and food additive bans across markets, as well as how and why consumers are responding to product and pricing changes," said Marsha McGraw, Global Managing Director, NIQ.

Unmatched Product Granularity, Global Relevance

NPI enables brands and retailers to spot trends early, personalize experiences and accelerate innovation with confidence by translating billions of product data points into structured claims, formulations, dietary indicators, and certifications—giving clients a clearer understanding of what shoppers care about and why. Key capabilities include:

Regulatory Readiness: Attribute-level data helps manufacturers and suppliers stay in tune with evolving global regulations: navigating tariffs, origin labeling, and food additive bans across markets.
Faster Innovation: NPI helps clients spot emerging trends and respond with the right claims, ingredients, and formats to influence consumer choice and drive faster time-to-market.
Shopper Personalization: Retailers use NPI's granular attribution data to elevate category management, optimize shelf layouts, and deliver personalized shopper experience that drives loyalty and conversion.

AI-Powered Intelligence, Global Scale

NPI is part of NIQ's broader effort to modernize the industry's understanding of what drives purchase decisions. By combining comprehensive retail measurement with next-gen AI tools, NIQ offers CPG brands and retailers a unified "source of truth” to optimize strategy, product development, and go-to-market execution.

This expansion is also a key milestone in NIQ's transformation, reinforcing its position as the consumer intelligence partner for approximately 23,000 clients globally, including many of the world's top retailers and brands.

To explore NPI and request a demo, visit here.

About NIQ:

NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together two industry leaders with unparalleled global reach. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $ 7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.

For more information, please visit www.niq.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508570595/en/

Contacts

Media Contact: Sweta.Patra@nielseniq.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom